ロード中...
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However, gemcitabine- and 5-fluorouracil-based therapi...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5793409/ https://ncbi.nlm.nih.gov/pubmed/29386069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0551-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|